News Release
ResearchArticle Cites Cleanascite™ for ProteomicScreening of Novel Biomarkers in Bile
MONMOUTHJUNCTION, NJ,March22, 2023 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their lipidclearance sample preparation technology for proteomic screening ofnovel biomarkers in bile fluid.
Thecitation is:
QinWH, Liu JT, Wang SP, Yang ZS, Wang KK, Hu B. Antibodyarray-based proteomic screening of novel biomarkers in malignantbiliary stricture.Cancer Biomark. 2022;33(3):359-368. doi: 10.3233/CBM-210095. PMID:34542063.
Distinguishingbetween benign and malignant bile duct strictures has long been adiagnostic challenge in clinical practice. Bileis the immediate biofluid for malignant tumors involving the bileduct, so tumor-related proteins may become detectable in bile ratherthan serum, especially during earlier stages of disease. Thus themolecular diagnosis of malignant biliary stricture using biomarkersin bile has been the subject of intensive investigation. Thisstudy aimed to discover novel biomarkers in bile to improve thediagnostic accuracy of malignant biliary strictures. Proteinprofiles of the bile were analyzed with a semi-quantitative humanantibody array of 440 proteins. The article states “…bilewas collected upstream from the biliary stricture, then mixed withPBS containing 0.1% Tween 20 and a protease inhibitor cocktail …,the supernatant was mixed with Cleanascite™ (Biotech Support Group,NJ, USA) to remove lipids. The article concludes that twenty proteinswere found differentially expressed in malignant versus benignbiliary strictures, 6 of which were identified by Venn diagramanalysis to be up-regulated regardless of the location of biliarystrictures. Lipocalin-2, P-cadherin and CA19-9 were identified as agroup of markers best distinguishing malignant from benignstrictures.
“Inthis important clinical problem, it is great to see that Cleanascite™efficiently removed lipids from bile fluid, allowing for proteomeanalysis using antibody-based arrays.” states Swapan Roy, Ph.D.,President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
Keywords
bileduct strictures, malignant biliary strictures, malignantversus benign biliary strictures,bile lipid removal, Cleanascite™,
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal.From these innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
ForBusiness Development, Contact:
MatthewKuruc 732-274-2866 [email protected]